MedTrace Logo

Effects of Energy Drinks on Cardiovascular Endpoints

NCT07212803 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-11-26

No results posted yet for this study

Summary

This is a clinical trial looking at the impact of energy drinks on heart related parameters. The study will enroll 3 participants who will be exposed to 8 different interventions.

Conditions

  • Healthy Volunteers
  • Safety After Oral Intake

Interventions

DIETARY_SUPPLEMENT

Energy Drink B

568 mL caffeine- and taurine-containing commercially available beverage (Formula B)

DIETARY_SUPPLEMENT

Control Product + Taurine

Control product with 4000 mg taurine powder

DIETARY_SUPPLEMENT

Control Product + Caffeine + Taurine

Control product with 320 mg caffeine + 4000 mg taurine powder

DIETARY_SUPPLEMENT

Lower Dose Energy Drink A

591 mL caffeine- and taurine-containing commercially available beverage (Formula A)

DIETARY_SUPPLEMENT

Energy Drink A + Placebo Capsule

1000 mL caffeine- and taurine-containing commercially available beverage (Formula A) consumed with placebo capsule

DRUG

Placebo Drink + Moxifloxacin Capsule

Placebo drink with 400 mg moxifloxacin capsule

DIETARY_SUPPLEMENT

Placebo Drink + Caffeine Capsule

Placebo drink with 320 mg caffeine capsule

OTHER

Placebo Drink + Placebo Capsule

Placebo drink with placebo capsule

Sponsors & Collaborators

  • University of the Pacific

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2026-03-31
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07212803 on ClinicalTrials.gov